A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies

← catalyst calendar

NCT04104672 · readout ≤ 285 d

Sponsored by Arcus Biosciences, Inc. (industry) · RCUS — their whole pipeline →.

Phase

Phase 1

Status

Active, not recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

196actual

Sites

Country

United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2019-11-06

actual

When the study began enrolling

Primary completion

May 2027

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

May 2027

estimated

The whole study's end, after follow-up

First posted

2019-09-26

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-02

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Advanced Pancreatic Cancer

Interventions

Drug: AB680
Drug: Zimberelimab — also filed as AB122
Drug: Nab-paclitaxel — also filed as Abraxane
Drug: Gemcitabine — also filed as Gemzar

Primary outcomes

what the primary-completion date above is the date OF

Number of participants with Treatment Emergent Adverse Events (TEAEs)

measured From first dose date to 90 days after the last dose (approximately 1 year)

Number of Participants With Dose Limiting Toxicities

measured From First dose to day 28

Publications

PMID 41912809 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · RCUS's whole pipeline · Catalyst calendar · Every registered study · What changed